IQWiG General Methods 8.0: new version in force
IQWiG General Methods 8.0 entered force in December 2025, introducing new methods for hospital minimum volume standards and HTA assessment.
IQWiG (German HTA) · Germany
Source
IQWiG (German HTA)
Regulation
Category
Type · Breadth
Date
Expert panel highlights opportunities for improving cancer studies
IQWiG publishes Cancer Medicines Forum workshop results proposing a roadmap for systematic implementation of cancer treatment optimization studies.
IQWiG (German HTA) · GermanyMinimum volume standards in hospitals: the first IQWiG projects have started
IQWiG received six commissions from the Federal Ministry of Health to develop scientific recommendations for minimum volume standards in hospital care under the German Hospital Reform Act 2024.
IQWiG (German HTA) · GermanyIQWiG assessment: linvoseltamab for relapsed or refractory multiple myeloma – unmet evidence need
IQWiG notes linvoseltamab received conditional marketing authorisation in April 2025 but comparative evidence is lacking until 2026.
IQWiG (German HTA) · GermanyLecanemab for early-stage Alzheimer's disease: IQWiG benefit assessment concludes no added benefit
IQWiG's benefit assessment of lecanemab for early-stage Alzheimer's disease, based on previously unpublished manufacturer data, finds no proven added benefit over current standard care.
IQWiG (German HTA) · GermanyEU HTA Regulation: first joint clinical assessment completed (tovorafenib)
IQWiG completed the first joint clinical assessment under the new EU HTA process for tovorafenib in paediatric low-grade glioma, approved by the Member State Coordination Group.
IQWiG (German HTA) · GermanyTrastuzumab deruxtecan for gastric cancer: HTA assessment of considerable added benefit
IQWiG determines considerable added benefit of trastuzumab deruxtecan for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma based on DESTINY-Gastric04 trial.
IQWiG (German HTA) · Germany
Showing 7 of 7 tracked updates
Health-tech only